Sensing Environmental Lipids by Dendritic Cell Modulates Its Function

Journal of Immunology

Volumn 172, Issue 1, 2004, Pages 54-60

  Coutant, Frédéric ^a   Agaugué, Sophie ^a   Perrin Cocon, Laure ^a   André, Patrice ^a   Lotteau, Vincent ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; FATTY ACID; INTRALIPID; LIPID; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACUTE PHASE RESPONSE; AGGRESSION; ARTICLE; BIOCHEMICAL COMPOSITION; BIOSENSOR; CELL DIFFERENTIATION; CELL MATURATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DENDRITIC CELL; EMULSION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNITY; MONOCYTE; OXIDATION; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0347994961     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.1.54     Document Type: Article

References (38)

1. Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunol. Today 15:74.
2. Cabana, V. G., J. N. Siegel, and S. M. Sabesin. 1989. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 30:39.
3. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:20963.
4. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:152.
5. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96:2758.
6. Perrin-Cocon, L., F. Coutant, S. Agaugue, S. Deforges, P. Andre, and V. Lotteau. 2001. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J. Immunol. 167:3785.
7. Kume, N., M. I. Cybulsky, and M. A. Gimbrone, Jr. 1992. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90:1138.
8. Takahara N., A. Kashiwagi, H. Maegawa, and Y. Shigeta. 1996. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 45:559.
9. Ryborg, A. K., B. Deleuran, H. Sogaard, and K. Kragballe. 2000. Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes. Acta Derm. Venereol. 80:242.
10. 2 activity in endothelial cell-induced modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA 82:3000.
11. Memon, R. A., I. Staprans, M. Noor, W. M. Holleran, Y. Uchida, A. H. Moser, C. Grunfeld. 2000. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 20:1536.
12. Steinbrecher, U. P., and P. H. Pritchard. 1989. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J. Lipid Res. 30-305
13. Coutant, F., L. Perrin-Cocon, S. Agaugue, T. Delair, P. Andre, and V. Lotteau. 2002. Mature dendritic cell generation promoted by lysophosphatidylcholine. J. Immunol. 169:1688.
14. Lenz, M. L., H. Hughes, J. R. Mitchell, D. P. Via, J. R. Guyton, A. A. Taylor, A. M. Gotto, Jr., and C. V. Smith. 1990. Lipid hydroperoxy and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein. J. Lipid Res. 31:1043.
15. Yamamoto, S. 1992. Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta 1128:117.
16. Nagy, L., P. Tontonoz, J. G. Alvarez, H. Chen, and R. M. Evans. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229.
17. Huang, J. T., J. S. Welch, M. Ricote, C. J. Binder, T.M. Willson, C. Kelly, J. L. Witztum, C. D. Funk, D. Conrad, and C. K. Glass. 1999. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400:378.
18. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79.
19. Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82.
20. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans. 2001. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7:48.
21. Lehmann, J. M., L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 270:12953.
22. Willson, T. M., J. E. Cobb, D. J. Cowan, R. W. Wiethe, I. D. Correa, S. R. Prakash, K. D. Beck, L. B. Moore, S. A. Kliewer, and J. M. Lehmann. 1996. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39:665.
23. Kliewer, S. A., K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771.
24. Daynes, R. A., and D. C. Jones. 2002. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2:748.
25. Gosset, P., A. S. Charbonnier, P. Delerive, J. Fontaine, B. Staels, J. Pestel, A. B. Tonnel, and F. Trottein. 2001. Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells. Eur. J. Immunol. 31:2857.
26. Nencioni, A., F. Grunebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart. 2002. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ. J. Immunol. 169:1228.
27. Faveeuw, C., S. Fougeray, V. Angeli, J. Fontaine, G. Chinetti, P. Gosset, P. Delerive, C. Maliszewski, M. Capron, B. Staels, et al. 2000. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. 486:261.
28. Tontonoz, P., L. Nagy, J. G. Alvarez, V. A. Thomazy, and R. M. Evans. 1998. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241.
29. Shi, Y., M. Hon, and R. M. Evans. 2002. The peroxisome proliferator-activated receptor δ an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl. Acad. Sci. USA 99:2613.
30. Robinson, C. E., X. Wu, Z. Nawaz, S. A. Onate, and J. M. Gimble. 1999. A corepressor and chicken ovalbumin upstream promoter transcriptional factor proteins modulate peroxisome proliferator-activated receptor-γ2/retinoid X receptor α-activated transcription from the murine lipoprotein lipase promoter. Endocrinology 140:1586.
31. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915.
32. Ross, R. 1999. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:115.
33. Hamilton, T. A., G. P. Ma, and G. M. Chisolm. 1990. Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor-α mRNA in stimulated murine peritoneal macrophages. J. Immunol. 144:2343.
34. Ohlsson, B. G., M. C. Englund, A. L. Karlsson, E. Knutsen, C. Erixon, H. Skribeck Y. Liu, G. Bondjers, and O. Wiklund. 1996. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-κB to DNA and the subsequent expression of tumor necrosis factor-α and interleukin-1β in macrophages. J. Clin. Invest. 98:78.
35. Panther, E., M. Idzko, S. Corinti, D. Ferrari, Y. Herouy, M. Mockenhaupt, S. Dichmann, P. Gebicke-Haerter, F. Di Virgilio, G. Girolomoni, and J. Norgauer. 2002. The influence of lysophosphatidic acid on the functions of human dendritic cells. J. Immunol. 169:4129.
36. McIntyre, T. M., A. V. Pontsler, A. R. Silva, A. St Hilaire, Y. Xu, J. C. Hinshaw, G. A. Zimmerman, K. Hama, J. Aoki, H. Arai, and G. D. Prestwich. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl. Acad. Sci. USA 100:131.
37. Schwarzer, E., H. Kuhn, E. Valente, and P. Arese. 2003. Malaria-parasitized erythrocytes and hemozoin nonenzymatically generate large amounts of hydroxy fatty acids that inhibit monocyte functions. Blood 101:722.
38. Aliberti, J., S. Hieny, C. Reis e Sousa, C. N. Serhan, and A. Sher. 2002. Lipoxinmediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3:76.